Drug companies' patient-assistance programs - Helping patients or profits?

New England Journal of Medicine

Volumn 371, Issue 2, 2014, Pages 97-99

  Howard, David H ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; DRUG COST; DRUG INDUSTRY; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; LEGAL LIABILITY; MEDICOLEGAL ASPECT; PATIENT ADVOCACY; PATIENT ASSISTANCE PROGRAM; PRIORITY JOURNAL; PURCHASING; SHORT SURVEY;

COST SHARING; DRUG COSTS; DRUG INDUSTRY; FINANCIAL SUPPORT; HUMANS; INSURANCE, HEALTH; PRESCRIPTION FEES; UNITED STATES; UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICES;

EID: 84903886381     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1401658     Document Type: Article

References (5)

1. Provenge financial coverage. Seattle: Dendreon (http://www.provenge.com/ reimbursement.aspx).
2. Visante. How copay coupons could raise prescription drug costs by $32 billion over the next decade. November 2011 (http:// www.pcmanet.org/images/stories/ uploads/2011/Nov2011/ visante%20copay%20coupon%20study.pdf).
3. Pavenik N. Do pharmaceutical prices respond to potential patient out-of-pocket expenses? Rand J Econ 2002;33:469-87.
4. Office of Inspector General, Department of Health and Human Services. Publication of OIG special advisory bulletin on patient assistance programs for Medicare Part D enrollees. Fed Regist 2005;70:70623-28.
5. Sebelius K. Letter from the Secretary of Health and Human Services to Rep. Jim Mc- Dermott, October 30, 2013 (http://op.bna.com/hl.nsf/id/etor-9czj72/ $File/case.pdf).